CN112057536B - Traditional Chinese medicine composition for preventing or/and treating dyslipidemia and application thereof - Google Patents
Traditional Chinese medicine composition for preventing or/and treating dyslipidemia and application thereof Download PDFInfo
- Publication number
- CN112057536B CN112057536B CN202010854245.6A CN202010854245A CN112057536B CN 112057536 B CN112057536 B CN 112057536B CN 202010854245 A CN202010854245 A CN 202010854245A CN 112057536 B CN112057536 B CN 112057536B
- Authority
- CN
- China
- Prior art keywords
- parts
- blood
- dyslipidemia
- traditional chinese
- phlegm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for preventing or/and treating dyslipidemia and application thereof, wherein the composition comprises the following raw materials: coptis root, frankincense, myrrh, dragon's blood, rhizoma pinellinae praeparata, fructus trichosanthis, gynostemma pentaphylla, poria cocos and dioscorea nipponica. The traditional Chinese medicine composition is suitable for the condition of dyslipidemia, particularly for the symptom of hyperlipidemia, can be prepared into any one of common oral dosage forms and health care products, has the effects of reducing phlegm and activating blood, descending the turbid and dredging collaterals, improves dyslipidemia, achieves the aim of obviously reducing blood fat, and is particularly suitable for the application of phlegm-blood stasis type dyslipidemia.
Description
Technical Field
The invention relates to a traditional Chinese medicine composition and a preparation method thereof, in particular to a traditional Chinese medicine composition for treating dyslipidemia and a preparation method thereof, and belongs to the field of traditional Chinese medicines.
Background
The disordered state of blood fat can create an environment for the occurrence and development of atherosclerosis. Adult-term hyperlipidemia increases the subsequent risk of coronary heart disease in a dose-dependent manner, and adults chronically exposed to non-high density lipoprotein cholesterol may increase the risk of future coronary heart disease. Clinical treatment experiments and epidemiological related studies of various lipid-lowering drugs have also confirmed the relationship between serum cholesterol levels and coronary heart disease risk. Meanwhile, hyperlipidemia is also an important condition for promoting diseases such as diabetes and periodontitis. Studies have shown that effective control and treatment of hyperlipidemia can effectively reduce mortality.
The retrospective clinical data of the traditional Chinese medicine treatment of dyslipidemia are collected and analyzed by the perizoic disease and the like, and the combination of phlegm and blood stasis is found to be the syndrome type with the highest frequency in the current dyslipidemia research, and the turbid phlegm and the blood stasis are the pathological factors with the highest frequency respectively. The hawthorn, the salvia miltiorrhiza and the rhizoma alismatis in the traditional Chinese medicine treatment are respectively the most frequent treatment medicines. While the statin drugs and the fibrate drugs in western medicine treatment are mainly used in clinic, although the western medicine products have obvious effect of improving dyslipidemia, no relevant description for obviously improving the pathological state of patients with 'phlegm-blood stasis' is provided.
The existing medicine market for treating phlegm-blood stasis type blood lipid abnormality mainly comprises common Chinese patent medicines such as Zhibitai capsules, Naoxintong capsules, Yindan Xinnaotong soft capsules and the like, wherein the Zhibitai capsules play the main effects of promoting blood circulation and removing blood stasis by using hawthorn and red yeast rice, but the two medicines have small blood circulation promoting force and do not have the function of dredging collaterals, and the prevention and control of other complications in the next step are not described with obvious effects; the Naoxintong capsule is used for treating the heart and brain diseases with the side weight of qi deficiency and blood stasis; the Yindan Xinnaotong soft capsule emphasizes the 'qi stagnation and blood stasis' type cardiovascular and cerebrovascular diseases, and is found to have the effect of improving the hyperlipemia in some researches, but the Yindan Xinnaotong soft capsule is not the main curative effect of the hyperlipemia, and the pathological factors of 'phlegm turbidity' are not described with obvious effect.
Disclosure of Invention
The invention aims at solving the technical problems of the existing medicines for treating dyslipidemia, especially for treating phlegm-blood stasis intermingled dyslipidemia, and provides a traditional Chinese medicine composition for preventing or/and treating dyslipidemia and application thereof. The composition has high curative effect on treating dyslipidemia and has no toxic or side effect.
In order to achieve the purpose of the invention, the invention provides a traditional Chinese medicine composition for preventing or/and treating dyslipidemia on one hand, which comprises the following raw materials: coptis root, frankincense, myrrh, dragon's blood, pinellia tuber, snakegourd fruit, gynostemma pentaphylla, tuckahoe and dioscorea nipponica.
The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 3-12 parts of coptis chinensis, 6-15 parts of frankincense, 6-15 parts of myrrh, 3-12 parts of dragon's blood, 3-9 parts of pinellia ternate, 6-15 parts of snakegourd fruit, 10-30 parts of gynostemma pentaphylla, 10-30 parts of poria cocos and 10-30 parts of dioscorea nipponica.
Particularly, the weight part ratio of the raw material medicines is preferably as follows: 3-9 parts of coptis chinensis, 6-9 parts of frankincense, 6-9 parts of myrrh, 3-9 parts of dragon's blood, 6-9 parts of pinellia ternate, 9-15 parts of snakegourd fruit, 15-30 parts of gynostemma pentaphylla, 15-30 parts of poria cocos and 10-30 parts of dioscorea nipponica.
In particular, the raw material medicines comprise the following components in parts by weight: coptis root 6, frankincense 9, myrrh 9, dragon's blood 6, pinellia tuber 9, snakegourd fruit 15, gynostemma pentaphylla 15, poria cocos wolf 30 and dioscorea nipponica 15.
Particularly, the dyslipidemia refers to dyslipidemia if the fasting TC, TG and LDL-C, HDL-C meet any one of the conditions, wherein the TC is more than or equal to 5.18 mmol/L; TG is more than or equal to 1.70 mmol/L; LDL-C is more than or equal to 3.37 mmol/L; HDL-C is less than 1.04mmol/L (according to Chinese guidelines for the prevention and treatment of adult dyslipidemia); that is to say, the fasting TC is more than or equal to 5.18mmol/L, TG is more than or equal to 1.70mmol/L, LDL-C is more than or equal to 3.37mmol/L or HDL-C is less than 1.04mmol/L, and the condition meeting any one of the above conditions is dyslipidemia (according to Chinese guidelines for preventing and treating adult dyslipidemia).
In particular, the dyslipidemia is phlegm-blood stasis type dyslipidemia.
In particular, the pinellia ternate is prepared from rhizoma pinelliae praeparata; selecting complete snakegourd fruit from the snakegourd fruit; the Olibanum is parched Olibanum, preferably vinegar parched Olibanum; the Myrrha is prepared from parched Myrrha, preferably Vinegar parched Myrrha.
The rhizoma pinellinae praeparata is prepared by processing raw pinellia ternate with liquorice, lime and the like in summer in a modern processing technology, so that the toxicity of the raw rhizoma pinellinae praeparata can be obviously reduced, and the effects of drying dampness and reducing phlegm are enhanced. Compared with the properties of pericarpium Trichosanthis, semen Trichosanthis and radix Trichosanthis, fructus Trichosanthis has the effects of relieving chest stuffiness, resolving hard mass, removing phlegm and resolving stagnation. Crude frankincense and myrrh are usually used externally, and are more suitable for oral administration after being fried, and are used for regulating qi and activating blood circulation.
Researchers in traditional Chinese medicine have actively explored and researched the aspects of treating dyslipidemia and regulating blood fat, mainly focus on the aspects of promoting blood circulation, reducing phlegm, tonifying qi and the like, and take hawthorn, red yeast rice and the like as main medicines. However, in clinical treatment, the inventor finds that phlegm turbidity and blood stasis are often in the same place, and are also accompanied by channel blockage, and other complications are easy to appear, so that the formula is named as the qi longxue pulse health formula by taking the concept of reducing phlegm and activating blood, and descending turbidity and dredging collaterals as the treatment rule of treating phlegm and blood stasis at the same time. Wherein, the dragon's blood which is good at promoting blood circulation and the yam which has stronger function of dredging collaterals are used as monarch drugs, the dragon's blood is named as ' Qi Jie ' in the ancient times, and the dragon's character of the yam is named as ' Qi Long '. Pinellia tuber, rhizoma Pinelliae is bitter and pungent with the effect of warming and drying, eliminating dampness and phlegm, regulating stomach and lowering adverse qi, and stomach qi and descending can generate phlegm without source; the snakegourd fruit has the effects of relieving chest stuffiness, regulating qi, eliminating phlegm, resolving masses, moistening and preventing pinellia ternata from being excessively dry; frankincense has the effects of regulating qi and activating blood, myrrh has the effects of removing blood stasis and regulating blood, and helps monarch drugs to promote blood circulation, and is used as ministerial drugs. Tuckahoe has the effects of strengthening spleen and excreting dampness and helping to resolve phlegm; gynostemma pentaphylla has the effects of invigorating spleen, regulating qi, tonifying qi, activating blood circulation and enhancing properties of monarch drugs and minister drugs, and is an adjuvant drug together. Phlegm and blood stasis are combined together, so they tend to stagnate and transform into heat, and Huang Lian is bitter in taste and cold in nature, and can clear heat after drying dampness, so it is a guiding drug. The medicines in the formula are used for treating phlegm and blood stasis, and have the effects of reducing phlegm and activating blood, descending turbid and dredging collaterals, and are particularly suitable for treating blood lipid abnormality caused by intermingled phlegm and blood stasis.
The coptis chinensis is cold in nature; is bitter in taste; the heart, gallbladder, spleen, stomach and large intestine meridians entered in ren Zhai Zhi Fang (Renzhai Zhi Fang): has the functions of removing heart orifice and blood stasis and clearing heat and drying dampness, purging fire and removing toxicity. Can be used for treating hyperpyrexia due to pathogenic heat entering heart meridian; dysphoria; epistaxis due to delirium or excessive heat forcing blood flow; dampness-heat fullness, vomiting, acid regurgitation, dysentery, jaundice, high fever, coma, hyperactivity of heart-fire, vexation, insomnia, blood heat, hematemesis, conjunctival congestion, toothache, diabetes, carbuncle, furuncle; it is used externally to treat eczema, eczema and purulent ear canal. Huang Lian (Chinese goldthread) processed with wine is good at clearing heat in upper energizer. It can be used for treating conjunctival congestion and aphtha. The Coptidis rhizoma mainly contains alkaloids such as berberine, coptisine, epiberberine, berberrubine, jateorhizine, magnoflorine, methyl coptisine, tetrandrine, and african tetrandrine, and optionally contains obacunone, ferulic acid, and phellodendron lactone.
Modern pharmacological research shows that the coptis has the effects of resisting bacteria and fungi, resisting viruses, resisting inflammation, resisting diarrhea and the like. The coptis decoction has the inhibition effect on influenza virus PR8 strains, influenza A virus 56-S8 strains, methylene virus FMl strains, influenza B virus Lee strains and influenza virus 1233 strains; has effect in inhibiting hepatitis B virus DNA. The research shows that the coptis chinensis has the effect of reducing blood fat, and the high-fat feed fed to rats shows that the coptis chinensis can effectively reduce the blood fat level of experimental rats. Clinical observation and research prove that the rosuvastatin and the berberine can effectively improve the hyperlipidaemia.
Ban Xia is pungent in flavor, warm in nature, toxic and enters spleen, stomach and lung meridians. Cloud of famous physicians' bibliography: pinellia ternate has the effects of eliminating phlegm and phlegm, lowering adverse flow of qi, relieving epigastric and thoracic diaphragms, relieving cough and ascending qi, treating urgent pain and lump in the lower heart, and preventing vomiting due to frequent vomiting, and has the effects of eliminating dampness and phlegm, lowering adverse flow of qi and preventing vomiting, relieving lump and eliminating stagnation and relieving swelling and pain for external use. It is mainly used for treating cough with dyspnea due to excessive phlegm, wind-phlegm vertigo, phlegm-fluid dizziness and palpitation, phlegm syncope headache, emesis and regurgitation, chest and gastric stuffiness, globus hystericus, and carbuncle and phlegm nodule. Jiang ban Xia is mostly used for checking adverse rise of qi and arresting vomiting; fa ban Xia is mainly used to dry dampness and resolve phlegm. Pinellia ternata is a common traditional Chinese medicine, and the decoction piece formula and the traditional Chinese medicine have larger production application, belong to better medicines for warming cold and resolving phlegm, and are difficult to replace by other medicines.
Ban Xia is famous for resolving phlegm, i.e. it has pungent flavor, so it is indicated for the pathological state of phlegm caused by stagnation of water-damp phlegm-saliva and can be treated with ban Xia. Among processed products of pinellia ternata, rhizoma pinelliae preparata can further improve the efficacy of reducing phlegm.
The tuber of pinellia contains volatile oil, small amount of fat (34% of fatty acid is solid acid and 66% of fatty acid is liquid acid), starch, nicotine, mucus, aspartic acid, glutamic acid, arginine, beta-aminobutyric acid and other amino acids, beta-sitosterol, choline, daucosterol, 3, 4-dihydroxybenzaldehyde, alkaloid with similar pharmacological action to that of curainine and nicotine, and substance with similar protoanemonin irritation to skin. Modern pharmacological studies show that pinellia ternata has the effects of relieving cough, promoting vomiting, inhibiting glandular secretion, resisting fertility, inhibiting protease, promoting cell division and lowering blood pressure.
Snakegourd fruit is a perennial grass vine of the cucurbitaceae family, and the traditional Chinese medicine snakegourd fruit is mature pericarp and seed thereof. The fruit is cut off with the handle in autumn when the fruit is ripe, and then hung and dried for application. The snakegourd fruit is sweet in nature and flavor and cold in property, enters lung, stomach and large intestine channels, has the effects of clearing lung heat and eliminating phlegm, and regulating qi and relieving chest stuffiness, and is mainly used for treating lung heat cough, turbid phlegm, yellow and thick phlegm, chest stuffiness and pain, chest fullness and fullness, acute mastitis, pulmonary abscess, intestinal abscess swelling and pain and constipation. According to analysis, the chemical components of the snakegourd fruit mainly comprise triterpenoid saponin, organic acid, resin, sugar, fatty oil, pigment and the like. The pharmacological research shows that the compound has the advantages of,
the total amino acids in the pericarpium Trichosanthis have expectorant effect; the laxative substances in the meaning of trichosanthes have the function of purgation; it also has effects in reducing blood cholesterol and triglyceride, increasing coronary blood flow, and dilating coronary artery; it also has antibacterial, anticancer, antiulcer, and antiaging effects. The trichosanthes kirilowii maxim has the effects of reducing blood cholesterol and triglyceride and dilating coronary artery, and is creatively applied to the treatment of blood lipid abnormality caused by phlegm-blood stasis.
Frankincense is slightly cold in nature, pungent, bitter and warm in taste. It enters heart, liver and spleen meridians and has the actions of promoting blood circulation and qi circulation; inducing menstruation to relieve menalgia; the efficacy of detumescence and promoting granulation. Can be used for treating pain of heart and abdomen, spasm of tendons and vessels, traumatic injury, skin ulcer, carbuncle, and swelling and pain; it can be used topically for detumescence and granulation promotion. The main components of frankincense include resin, gum and volatile oil, which are good at moving and promoting qi and blood circulation, and myrrh is neutral in property and emphasizes on bitter taste and purgation, blood dissipation and blood stasis removal. The main components of mastic resin are free a, beta-mastic acid, combined mastic acid, mastic resin hydrocarbon, O-acetyl-beta-mastic acid, O-acetyl-a-mastic acid, etc.; modern pharmacological research shows that the frankincense volatile oil has an obvious analgesic effect; the frankincense can also promote the increase of multinucleated white blood cells, so as to phagocytize dead blood cells and dead cells, improve metabolism and further play a role in diminishing inflammation and preventing corrosion.
The myrrh is bitter in taste and neutral in nature, enters liver channel, has the effects of removing blood stasis and relieving pain, and externally dispersing swelling and promoting granulation, and is mainly used for treating traumatic blood stasis and swelling pain, carbuncle and cellulitis swelling pain, chest and abdomen pain; it is indicated for long-term sore without astringency. The main components of myrrh comprise resin, volatile oil, gum and the like, wherein most of myrrh resin can be dissolved in ether, wherein: the insoluble part contains alpha and beta bisaboloic acid, and the soluble part contains alpha, beta and gamma bisaboloic acid, alpha and beta bisabolol, etc.; the volatile oil is easily resinified in air, and contains eugenol, m-cresol, cumaldehyde, allyl, dipentene, limonene, cinnamaldehyde, and hamoumarin; hydrolyzing the gum to obtain arabinose, galactose and xylose.
Modern pharmacological research shows that the myrrh water extract has an inhibiting effect on dermatophytes; the myrrh decoction can increase blood flow and reduce vascular resistance; moreover, the oleoresin can reduce the cholesterol content of male rabbit hypercholesterolaemia (caused by feeding hydrogenated vegetable oil), prevent plaque formation, and reduce rabbit weight. Similar to other oleoresin-containing substances, myrrh (usually in tincture) has some local irritation, and can be used in oral cavity lotion, or used for stimulating intestinal peristalsis when stomach and intestine are weak. .
The compatibility of Ru Xiang and Mo Yao is known in the formula Ru Xiang Zhi san (therapeutic treatment guideline). The compendium of materia Medica says: ru Xiang has the action of activating blood and Mo Yao has the action of dispersing blood, so they are indicated for each herb because they can alleviate pain, resolve swelling and promote tissue regeneration. The records of Western medicine of Zhongzhao: the two herbs are mutually reinforced and can reinforce the efficacy of herbs to promote the flow of qi and blood through the zang-fu organs and meridians, so they can be indicated for all kinds of pain in the heart, stomach, hypochondrium and joints. Frankincense and myrrh are both traditional Chinese medicines with the functions of promoting blood circulation and removing blood stasis, frankincense is warm in nature, myrrh is flat in nature, the frankincense and the myrrh are both pungent, bitter and fragrant in flavor, and enter heart, liver and spleen channels, and the frankincense and the myrrh are clinically commonly used pairs and have better curative effects of improving heart and abdomen pain, rheumatic arthralgia, amenorrhea and dysmenorrheal, traumatic injury and blood stasis pain and the like. Plays an important role in promoting blood circulation, removing blood stasis and dredging collaterals.
The dragon blood is also called dragon blood, is an ethanol extract of resin-containing wood of dracaena cochinchinensis of Liliaceae, is sweet, salty and neutral in taste, has the effects of activating blood circulation, dissipating blood stasis, relieving pain, stopping bleeding, promoting tissue regeneration, healing sore and the like, is one of the famous traditional Chinese medicines for activating blood circulation and dissipating blood stasis, and is mainly used for treating traumatic injuries and internal injury pain due to stasis; bleeding caused by trauma is not limited. The dragon's blood is a blood-activating eriodictyon which is a traditional Chinese medicine for activating blood and dissolving stasis and is proved to be capable of regulating abnormal lipid metabolism states of rats in recent experimental research. In addition, some compounds containing the dragon's blood component are proved to have positive regulation effect on blood fat level.
The main chemical component of the dragon blood is a mixture of resin ester and dragon blood resin tannin, and the content of the dragon blood resin tannin is about 57-82%; and amorphous haemaglutinin, yellow resina Draconis resin, insoluble resin, etc. Sanguis Draxonis has antifungal effect, and the soaking agent (1: 2) for treating blood stasis has different degrees of inhibiting effect on various pathogenic fungi such as Trichophyton violaceum, Trichophyton gypseum, and Trichophyton schoenleinii in test tube; the dragon's blood has strong hemostatic action, can obviously shorten the plasma recalcification time and increase the blood coagulation action.
Gynostemma pentaphyllum Makino, also known as Gynostemma pentaphyllum Makino, and Gynostemma pentaphyllum Makino. Sweet in nature and taste and slightly cold in nature. Enter lung, spleen, stomach, heart, kidney and large intestine meridians. Has the effects of strengthening the spleen, regulating qi, tonifying qi, activating blood circulation, reducing phlegm, relieving cough and the like, is mainly used for treating chronic bronchitis, infectious hepatitis, nephritis and gastroenteritis, and is mostly used as a tonic.
The effective component of herba Gynostemmatis is gypenoside which is isomer of protopanaxadiol and protopanaxatriol, and contains flavone and saccharide. The gynostemma pentaphylla has obvious functions of lowering cholesterol, triglyceride and low density lipoprotein, raising high density lipoprotein, promoting the action of oxidase in human body and raising cell activity, so that it has obvious effect of dilating blood vessel. Has good effects of regulating fat metabolism and preventing lipid from depositing on blood vessel wall. Through the research of scholars at home and abroad, the gypenosides have the effects of resisting platelet aggregation, reducing thromboxane B2(TXB2) and 5 hydroxytryptamine released by platelets, resisting oxygen free radicals, resisting lipid peroxidation, protecting ischemic myocardial injury, reducing blood fat and blood sugar and the like, and also have the protective effect on cerebral ischemia and central nervous system.
Poria, commonly known as Poria cocos, pine tuckahoe and Poria cocos wolf, is a fungus plant parasitic on pine roots, and is shaped like a sweet potato with black brown outer skin and white or pink inner side. The original biomass is dry sclerotium of Poria cocos (Schw.) wolf of Polyporaceae, and is mainly parasitic on root of Pinus massoniana or Pinus densiflora. Produced in Yunnan, Anhui, Hubei, Henan, Sichuan and other places. The ancient people called tuckahoe as a four-season magical medicine can play its unique effect regardless of cold, warm, wind and dampness by combining it with various medicines because of its very wide effect and no four seasons. Poria cocos, with sweet, bland and neutral nature, enters heart, lung and spleen meridians. Has effects of eliminating dampness, promoting diuresis, invigorating spleen, regulating stomach function, calming heart, and tranquilizing mind. Can be used for treating dysuria, edema, fullness, phlegm retention, cough, vomiting, nausea, diarrhea, spermatorrhea, stranguria with turbid urine, palpitation, and amnesia. Tuckahoe, which is different from other traditional Chinese medicines that induce diuresis directly, induces diuresis by strengthening the spleen and lung. Ling Gui Zhu gan Tang, Sijun Zi Tang and Siling Tang are all commonly used prescriptions with compatibility of Poria.
Poria comprises beta-pachyman (93% of dry weight) and triterpenes such as acetylpachymic acid, pachymic acid, and 3 beta-hydroxylanostatrienoic acid. In addition, it contains gum, chitin, protein, fat, sterol, lecithin, histidine, choline, lithium salt, etc.
Modern medical research shows that: the Poria water extract can obviously resist MTT reducing ability and microtubule structure disorder of nerve cell mitochondria caused by sodium azide, maintain cell mitochondria function and microtubule structure, slow aging, and prevent and treat neurodegenerative diseases such as senile dementia, vascular dementia and Parkinson's disease; pachyman can increase T-SOD and Cu-SOD activity in serum of aged rat, reduce MDA content, and has effects of resisting cold, relieving fatigue and delaying aging; the tuckahoe can obviously improve the immunologic function of a human body, can also enable oxygenated hemoglobin in capillaries to release more oxygen, supply enough oxygen to tissue cells (including skin, mucous membrane, hair and the like), delay cell aging, enable the cells to regenerate rapidly, moisten the skin, increase the elasticity and the luster, and further play roles in enhancing the youth activity and beautifying. The tuckahoe can enhance the immunity of the organism and has the effect of assisting in reducing phlegm by strengthening the spleen and excreting dampness in the compound recipe.
Rhizoma Dioscoreae Nipponicae is the rhizome of Dioscorea Nipponica Makino of Dioscorea of Dioscoreaceae, also known as Dioscorea Nipponica Makino, Dioscorea Panthaica Prain et Burkill, Dioscorea villosa, Curcuma rhizome, and caulis et folium Schefflerae Arboricolae, etc., has bitter taste and slight cold, enters liver and lung channels, has the main effects of dispelling pathogenic wind and removing dampness, relaxing muscles and tendons and dredging collaterals, promoting blood circulation and relieving pain, relieving cough and asthma, and promoting blood circulation and dredging collaterals, and can be used for treating rheumatalgia; numbness of limbs; chest stuffiness and pain; chronic tracheitis; traumatic injury; abuse; abscess and swelling. The main components of Ningpo Yam rhizome include dioscin, fine dioscin, sarsasaponin, 25-D-spirost-3, 5-diene, p-hydroxybenzyl tartaric acid, etc.
The modern pharmacological research of the dioscorea nipponica shows that the total saponins have the effects of relieving cough, eliminating phlegm and relieving asthma; the main component dioscin is proved to be capable of reducing blood cholesterol and blood pressure, delaying heart rate, enhancing cardiac contraction amplitude, increasing urine volume, reducing beta/alpha lipoprotein ratio, improving coronary circulation and regulating dyslipidemia in clinical and basic researches.
The traditional Chinese medicine composition is prepared by the following method:
1) mixing Coptidis rhizoma, Olibanum, Myrrha, rhizoma Pinelliae, fructus Trichosanthis, herba Gynostemmatis, Poria, and Ningpo Yam rhizome, adding water, heating the mixture, extracting for 2-4 times, filtering, and mixing filtrates to obtain mixed extractive solution;
2) concentrating the mixed extract to prepare a mixed concentrated solution;
3) pulverizing sanguis Draxonis to obtain sanguis Draxonis powder;
4) mixing the concentrated solution with sanguis Draxonis powder.
Wherein, the raw materials in the steps 1) and 3) comprise coptis chinensis, frankincense, myrrh, pinellia ternate, snakegourd fruit, gynostemma pentaphylla, poria cocos, dioscorea nipponica and dragon's blood in parts by weight: 3-12 parts of coptis chinensis, 6-15 parts of frankincense, 6-15 parts of myrrh, 3-12 parts of dragon's blood, 3-9 parts of pinellia ternate, 6-15 parts of snakegourd fruit, 10-30 parts of gynostemma pentaphylla, 10-30 parts of poria cocos and 10-30 parts of dioscorea nipponica.
Particularly, the weight part ratio of the raw material medicines is preferably as follows: 3-9 parts of coptis chinensis, 6-9 parts of frankincense, 6-9 parts of myrrh, 3-9 parts of dragon's blood, 6-9 parts of pinellia ternate, 9-15 parts of snakegourd fruit, 15-30 parts of gynostemma pentaphylla, 15-30 parts of poria cocos and 10-30 parts of dioscorea nipponica.
In particular, the raw material medicines comprise the following components in parts by weight: coptis root 6, frankincense 9, myrrh 9, dragon's blood 6, pinellia tuber 9, snakegourd fruit 15, gynostemma pentaphylla 15, poria cocos wolf 30 and dioscorea nipponica 15.
Wherein, the weight ratio of the total weight of the raw material mixture to the weight of the added water in each heating and extracting process in the step 1) is 1: 1-15.
Particularly, the heating extraction temperature is 60-100 ℃, and preferably 80-100 ℃; the heating extraction time is 1-5 h/time.
Particularly, the raw material mixture is added with water and uniformly mixed, and then is soaked for 20-90min, and then is heated and extracted.
Particularly, the soaking time is preferably 30-60min, and more preferably 30 min.
Wherein the concentration treatment in the step 2) is to perform reduced pressure evaporation concentration on the mixed extracting solution in a vacuum state to remove water, wherein the concentration temperature is 80-100 ℃, preferably 80 ℃, and the relative pressure during concentration is-0.05 to-0.1 MPa, preferably-0.05 to-0.095 MPa, and more preferably-0.07 MPa.
In particular, the concentration treatment in step 2) is a heating evaporation treatment of the mixed extract under normal pressure, i.e. under an absolute pressure of 1atm, the combined water extract is heated to evaporate water therein for concentration.
Wherein, the heating extraction in the step 1) is carried out according to the following steps:
1A) mixing the raw materials of coptis chinensis, frankincense, myrrh, pinellia ternate, snakegourd fruit, gynostemma pentaphylla, poria cocos and dioscorea nipponica, adding water for soaking, wherein the weight ratio of the added water to the mixed raw materials is (1-15) to 1, soaking for 20-90min, and then carrying out first heating extraction at the temperature of 60-100 ℃ for 1-5 h;
1B) filtering the mixed system for the first extraction to obtain a first extracting solution; adding water into the residue at least 1 time, and continuously extracting for at least 1 time, wherein the ratio of the weight of water added to the weight of the mixed raw materials is (1-15):1, the extraction temperature is 60-100 deg.C, and the extraction time is 1-5 h;
1C) filtering, and mixing filtrates to obtain the mixed extractive solution.
In particular, the soaking time in the step 1A) is preferably 30-60min, and more preferably 30 min; the ratio of the weight of the added water to the weight of the mixed raw materials is preferably (5-15):1, more preferably (6-12):1, and still more preferably (6-9): 1; the heating extraction time is preferably 2-5 h; the heating extraction temperature is preferably 80-100 ℃; the ratio of the weight of water added in each time to the weight of the mixed raw materials in the step 1B) is preferably (1-5) to 1; the extraction time is preferably 1-3h per heating; the temperature for extraction by heating is preferably 80-100 ℃.
Wherein the relative density of the mixed concentrated solution in the step 2) is 1.05-1.5, preferably 1.1-1.5, and further preferably 1.1-1.3; the particle size of the dragon's blood powder in the step 3) is less than 15 mu m.
Particularly, the pulverization in the step 3) is selected to be superfine pulverization; the particle diameter of the sanguis Draxonis powder after pulverizing is 1-15 μm, preferably 10-15 μm.
Also comprises drying to obtain dried active components of the composition.
Especially, the method also comprises the steps of drying the mixed concentrated solution to prepare mixed medicinal material powder, and then uniformly mixing the mixed medicinal material powder with the dragon's blood powder to prepare the traditional Chinese medicine composition for treating dyslipidemia.
The traditional Chinese medicine composition for treating blood lipid abnormality caused by phlegm-blood stasis can be prepared into clinically acceptable oral dosage forms with pharmaceutically acceptable auxiliary materials according to the traditional or modern production process. Such as capsule, tablet, granule, pill, oral liquid, etc. The pharmaceutical excipients used may be pharmaceutically acceptable carriers selected from the handbook of pharmaceutical excipients (handbook of pharmaceutical excipients, 2 nd edition, edited by A.Wade and P.J.Weller; published by American pharmaceutical Association, Washington and the pharmaceutical Press, London, 1994), such as starch, dextrin, lactose, microcrystalline cellulose, gelatin, sucrose, magnesium stearate, etc. The medicine needs to be taken for a long time clinically, is prepared into a solid preparation which is convenient to store and take by patients, and is more suitable for market demands. The preferable dosage forms are capsules, granules, tablets, pills, powders, oral liquids and the like.
The invention further provides application of any one of the compositions in preparation of a medicament and/or a health-care product for treating dyslipidemia.
The traditional Chinese medicine composition prepared by the method adopts a plurality of traditional Chinese medicines which are mutually matched according to the pathogenesis of phlegm-blood stasis type dyslipidemia (especially hyperlipidemia), and the active ingredients of the traditional Chinese medicines are mutually cooperated and synergized, so that the traditional Chinese medicine composition can eliminate phlegm and remove blood stasis, regulate menstruation, promote blood circulation and remove meridian obstruction and regulate the normal blood fat by effectively improving the pathological state of phlegm-blood stasis. The composition has high curative effect on treating dyslipidemia and has no toxic or side effect.
When the traditional Chinese medicine composition for phlegm-blood stasis combined dyslipidemia, which is prepared by the invention, is orally taken for 1-2 times a day, 3-6 g (composition, dry) each time, pregnant women are prohibited to take the composition, spicy food and wine are prohibited to take during medication, after the composition is continuously used for 2-4 weeks, total cholesterol, triglyceride, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol are obviously improved, dyslipidemia (TC, TG and HDL-C, LDL-C) is obviously improved, the area of atherosclerotic plaques is reduced or is not enlarged any more, and symptoms such as chest pain, chest distress, dizziness, headache and the like during attack are relieved.
The traditional Chinese medicine composition for treating blood lipid abnormality caused by intermingled phlegm and blood stasis has the following advantages:
1. the traditional Chinese medicine composition (Qi Longxue Maijian prescription) is used for symptomatic treatment aiming at the pathogenesis of phlegm-blood stasis type abnormal blood fat, the traditional Chinese medicine composition is prepared by compounding a plurality of traditional Chinese medicine components, the active ingredients of the medicines are mutually synergistic, and pinellia ternate, poria cocos, snakegourd fruit and the like in the prescription are directly aimed at turbid phlegm formed by greasy diet; the dragon's blood, frankincense and myrrh have good curative effects on blood stasis further caused by various pathological factors, and are particularly suitable for clinical syndromes of phlegm and blood stasis. The multi-link comprehensive treatment is adopted aiming at the formation reason of the phlegm-blood stasis type dyslipidemia, and the treatment effect is quick and the action is quick.
2. The traditional Chinese medicine composition has an obvious curative effect on dyslipidemia, and has the effect of activating blood and dredging collaterals due to the effects of promoting blood circulation and dredging collaterals of rhizoma dioscoreae nipponicae, dragon's blood, frankincense, myrrh and the like, and is particularly suitable for the later stage of phlegm and blood stasis and the state of channel blockage due to the effects of eliminating phlegm and drying dampness of pinellia ternate, snakegourd fruit, poria cocos and the like, so that the clinical complications of dyslipidemia are reduced, and the hospitalization rate, disability rate and death rate of related complications patients are reduced.
3. The traditional Chinese medicine composition for treating blood fat abnormality caused by phlegm and blood stasis (Qi Long blood vessel health prescription) is derived from an proved prescription obtained by long-time exploration and optimization of a doctor in the department of Huyuan of Guangan Men hospital, and through application in long-term clinical practice, the traditional Chinese medicine composition has the effect of remarkably regulating blood fat after being taken, does not have adverse reaction after being taken for a long time, has no toxic or side effect, is long in medicine taking time, simple in preparation process, obvious in stable product quality and convenient to use, and fills up the defect of a Chinese patent medicine market for treating blood fat abnormality caused by phlegm and blood stasis.
4. The traditional Chinese medicine composition for treating blood lipid abnormality with syndrome of phlegm and blood stasis (Qi Long blood vessel strengthening formula) achieves the purpose of improving blood lipid by reducing phlegm, activating blood, descending turbid and dredging collaterals, focuses on the improvement effect on the syndrome of phlegm and blood stasis, and can effectively prevent atherosclerosis, fatty liver and other diseases and complications caused by blood lipid abnormality.
5. The traditional Chinese medicine composition (Qi longxue Mai Jianfang) for treating blood lipid abnormality with syndrome of phlegm and blood stasis has the advantages of simple preparation method, mild process conditions, low cost and low cost, reduces the treatment cost of blood lipid abnormality, saves the clinical health and medical cost, is suitable for market popularization and application, and enables more patients to benefit from the traditional Chinese medicine composition.
Detailed Description
The invention will be further described with reference to specific embodiments, and the advantages and features of the invention will become apparent as the description proceeds. These examples are illustrative only and do not limit the scope of the present invention in any way. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention, and that such changes and modifications may be made without departing from the spirit and scope of the invention.
The beneficial effects of the drug of the present invention are further illustrated by the following test examples, which include pharmacodynamic tests of the drug of the present invention.
Example 1 preparation of Qi Longxue Mai Jian granule
1) Preparing raw material medicaments according to the following weight ratio (unit: x 10g)
Rhizoma Coptidis 6, Olibanum 9, Myrrha 9, sanguis Draxonis 6, rhizoma Pinelliae Preparata 9, fructus Trichosanthis 15, herba Gynostemmatis 15, Poria 30, and Ningpo Yam rhizome 15, wherein the Olibanum is vinegar parched Olibanum; myrrha is prepared by parching Myrrha with vinegar;
2) cleaning raw material medicines including coptis chinensis, frankincense, myrrh, pinellia ternate, snakegourd fruit, gynostemma pentaphylla, poria cocos and dioscorea nipponica, putting the cleaned raw material medicines into a multifunctional traditional Chinese medicine extraction kettle, uniformly mixing, adding tap water to soak for 30min (usually 20-90min), wherein the ratio of the weight of the added tap water to the weight (dry weight) of the medicinal material mixture is 9:1 (typically 1-15: 1);
3) starting a power supply of the multifunctional extraction kettle to heat, heating to 100 ℃, keeping the temperature, extracting for 3 hours at constant temperature, and filtering to obtain a first extracting solution for later use;
4) adding tap water into the filter residue for 1 time, heating and extracting for 1 time, wherein the ratio of the weight of the tap water added to the weight (dry weight) of the medicinal material mixture is 5:1 (generally 1-15:1), heating and extracting at 100 ℃ for 3h, and filtering to obtain a second extracting solution;
the heating and extracting temperature is not limited to 100 ℃, and other temperatures (such as 60-100 ℃, preferably 90-100 ℃) are all suitable for the invention.
5) Mixing the extractive solutions obtained in 2 times, making into mixed extractive solution, and vacuum evaporating and concentrating in a vacuum high-energy evaporation concentrator under reduced pressure to obtain concentrated extract, wherein the relative pressure of the reduced pressure concentration is-0.07 MPa (one atmosphere is 0, and the pressure during reduced pressure concentration is controlled to be-0.07 MPa relative to one atmosphere), the concentration temperature is 80 deg.C, and the mixed extractive solution is concentrated to obtain mixed concentrated solution with relative density of 1.2;
in addition to the concentration by evaporation under reduced pressure, the concentration method known in the art is suitable for the present invention, such as heating and evaporation under normal pressure. The relative density of the mixed concentrate is 1.05-1.5 and is suitable for the invention.
6) Drying the mixed concentrated solution at 45-50 deg.C until water content is lower than 5% (usually 1-4%), pulverizing, and sieving with 180 mesh sieve to obtain mixed medicinal powder;
7) micronizing sanguis Draxonis with micronizer to obtain sanguis Draxonis superfine powder with particle diameter less than 15 μm (usually 10-15 μm);
the superfine grinding is taken as an example for explaining the grinding of the dragon blood in the invention, and other grinding treatments are also applicable to the invention.
8) Mixing the mixed medicinal material powder, the dragon's blood ultrafine powder and the auxiliary material dextrin, using ethanol as an adhesive, granulating and drying to obtain the traditional Chinese medicine Qi Long Xuemaojian granule for treating dyslipidemia.
Example 2 preparation of Qi LONG XUEMAIJIAN pill
1) Preparing raw material medicaments according to the following weight ratio (unit: x 10g)
Coptis root 3, frankincense 6, myrrh 9, dragon's blood 9, rhizoma pinellinae praeparata 6, trichosanthes kirilowii 15, gynostemma pentaphylla 15, poria cocos 30 and dioscorea nipponica 30
2) Rinsing the medicinal materials including coptis chinensis, frankincense, myrrh, pinellia ternate, snakegourd fruit, gynostemma pentaphylla, poria cocos and dioscorea nipponica, putting the rinsed medicinal materials into a multifunctional traditional Chinese medicine extraction kettle, uniformly mixing the rinsed medicinal materials and the traditional Chinese medicine extraction kettle, adding tap water, and soaking the mixture for 60min, wherein the ratio of the weight of the added tap water to the weight (dry weight) of the medicinal material mixture is 6: 1;
3) starting a power supply of the multifunctional extraction kettle to heat, keeping the temperature at 80 ℃, extracting for 5 hours at constant temperature, and then filtering to obtain a first extracting solution for later use;
4) adding tap water into the filter residue for 2 times, and heating and extracting for 2 times, wherein the ratio of the weight of the tap water added to the weight (dry weight) of the medicinal material mixture is 4: 1 (generally 1-15:1), heating and extracting at 80 deg.C for 2h, and filtering to obtain 2 extractive solutions;
5) mixing the extractive solutions for 3 times, making into mixed extractive solution, and vacuum evaporating and concentrating in a vacuum high-energy evaporation concentrator under reduced pressure to obtain concentrated extract, wherein the relative pressure of the reduced pressure concentration is-0.05 MPa (one atmosphere is 0, and the pressure during reduced pressure concentration is controlled to be-0.05 MPa relative to one atmosphere), and concentrating the mixed extractive solution to obtain mixed concentrated solution with relative density of 1.3;
6) spray drying the mixed concentrated solution to obtain mixed medicinal powder;
7) micronizing sanguis Draxonis with micronizer to obtain sanguis Draxonis superfine powder with particle diameter less than 15 μm (usually 1-15 μm);
8) mixing the mixed medicinal material powder, the dragon's blood ultrafine powder and the auxiliary material refined honey, uniformly stirring, putting into a pill making machine for making pills, and then drying to obtain the traditional Chinese medicine Qi Long Xuemaojian concentrated pill for treating dyslipidemia.
Example 3 preparation of Qi LONG XUEMAIJIAN tablet
1) Preparing raw material medicaments according to the following weight ratio (unit: x 10g)
9 parts of coptis chinensis, 9 parts of frankincense, 6 parts of myrrh, 3 parts of dragon's blood, 9 parts of rhizoma pinellinae praeparata, 9 parts of fructus trichosanthis, 30 parts of gynostemma pentaphylla, 15 parts of poria cocos and 10 parts of dioscorea nipponica
2) Cleaning raw material medicines including coptis chinensis, frankincense, myrrh, snakegourd fruit, gynostemma pentaphylla, poria cocos and yam, putting the cleaned raw material medicines into a multifunctional traditional Chinese medicine extraction kettle, adding tap water to soak for 20min (usually 20-90min), wherein the ratio of the weight of the added tap water to the weight (dry weight) of the medicinal material mixture is 12:1 (usually 1-15: 1);
3) starting a power supply of the multifunctional extraction kettle to heat, heating to 80 ℃, keeping the temperature for extracting for 5 hours at constant temperature, and then filtering to obtain a first extracting solution for later use;
4) then adding tap water into the filter residue for 3 times, and heating and extracting for 3 times, wherein the ratio of the weight of the tap water added to the weight (dry weight) of the medicinal material mixture in each time is 1: 1 (generally 1-15:1), heating and extracting at 90 deg.C for 1h, and filtering to obtain 3 extractive solutions;
5) mixing the extractive solutions for 4 times, making into mixed extractive solution, and vacuum evaporating and concentrating in a vacuum high-energy evaporation concentrator under reduced pressure to obtain concentrated extract, wherein the relative pressure of the reduced pressure concentration is-0.095 MPa (one atmosphere is 0, and the pressure during reduced pressure concentration is controlled to be-0.095 MPa relative to one atmosphere), and the mixed extractive solution is concentrated to obtain mixed concentrated solution with relative density of 1.5;
6) drying the mixed concentrated solution at 45-50 deg.C until water content is lower than 5% (usually 1-4%), pulverizing, and sieving with 100 mesh sieve to obtain mixed medicinal powder;
7) micronizing sanguis Draxonis with micronizer to obtain sanguis Draxonis superfine powder with particle diameter less than 15 μm (usually 1-10 μm);
8) mixing the mixed medicinal material powder, the dragon's blood ultramicro powder and the auxiliary material dextrin, granulating by using ethanol, drying, and tabletting by using a tabletting machine to obtain the traditional Chinese medicine Qi Longxue Mai Jian tablet for treating dyslipidemia.
Example 4 preparation of Qi LONG XUEMAIJIAN Capsule
1) Preparing raw material medicaments according to the following weight ratio (unit: x 10g)
Coptis root 3, frankincense 15, myrrh 15, dragon's blood 3, rhizoma pinellinae praeparata 3, trichosanthes kirilowii 6, gynostemma pentaphylla 30, poria cocos 10 and dioscorea nipponica 30
2) Cleaning raw material medicines including coptis chinensis, frankincense, myrrh, snakegourd fruit, gynostemma pentaphylla, poria cocos and yam, putting the cleaned raw material medicines into a multifunctional traditional Chinese medicine extraction kettle, adding tap water, and soaking for 90min (usually 20-90min), wherein the weight ratio of the added tap water to the weight (dry weight) of the medicinal material mixture is 6:1 (usually 1-15: 1);
3) starting a power supply of the multifunctional extraction kettle to heat, heating to 80 ℃, keeping the temperature for extracting for 4 hours at constant temperature, and then filtering to obtain a first extracting solution for later use;
4) adding tap water into the filter residue for 1 time, and heating and extracting for 1 time, wherein the ratio of the weight of the added tap water to the weight (dry weight) of the medicinal material mixture is 5:1 (generally 1-15:1), heating and extracting at 80 deg.C for 3h, and filtering to obtain a second extractive solution;
5) mixing the extractive solutions obtained in 2 times, making into mixed extractive solution, and vacuum evaporating and concentrating in a vacuum high-energy evaporation concentrator under reduced pressure to obtain concentrated extract, wherein the relative pressure of the reduced pressure concentration is-0.07 MPa (one atmosphere is 0, and the pressure during reduced pressure concentration is controlled to be-0.07 MPa relative to one atmosphere), and concentrating the mixed extractive solution to obtain mixed concentrated solution with relative density of 1.1; the concentration temperature was 80 ℃.
6) Freeze-drying the mixed concentrated solution, then crushing and sieving by a 100-mesh sieve to prepare mixed medicinal material powder;
7) micronizing sanguis Draxonis with micronizer to obtain sanguis Draxonis superfine powder with particle diameter less than 15 μm (usually 1-10 μm);
8) the traditional Chinese medicine Qi longxue Mai jian capsule for treating dyslipidemia is prepared by mixing the mixed medicinal material powder, the dragon's blood ultramicro powder and the auxiliary material microcrystalline fiber and then filling the mixture into a gelatin hard capsule.
Example 5 preparation of Qi Longxue Mai Jian oral liquid
1) Preparing raw material medicaments according to the following weight ratio (unit: x 10g)
Rhizoma Coptidis 12, Olibanum 6, Myrrha 6, sanguis Draxonis 12, rhizoma Pinelliae Preparata 9, fructus Trichosanthis 15, herba Gynostemmatis 10, Poria 30, and Ningpo Yam rhizome 10
2) Cleaning raw material medicines including coptis chinensis, frankincense, myrrh, snakegourd fruit, gynostemma pentaphylla, poria cocos and yam, putting the cleaned raw material medicines into a multifunctional traditional Chinese medicine extraction kettle, adding tap water, and soaking for 60min (usually 20-90min), wherein the ratio of the weight of the added tap water to the weight (dry weight) of the medicinal material mixture is 9:1 (usually 1-15: 1);
3) starting a power supply of the multifunctional extraction kettle to heat, heating to 100 ℃, keeping the temperature for extracting for 3 hours at constant temperature, and then filtering to obtain a first extracting solution for later use;
4) adding tap water into the filter residue for 2 times, and heating and extracting for 2 times, wherein the ratio of the weight of the tap water added to the weight (dry weight) of the medicinal material mixture is 5:1 (generally 1-15:1), heating and extracting at 100 deg.C for 3 hr, and filtering to obtain 2 extractive solutions;
5) mixing the extractive solutions for 3 times, making into mixed extractive solution, and vacuum evaporating and concentrating in a vacuum high-energy evaporation concentrator under reduced pressure to obtain concentrated extract, wherein the relative pressure of the reduced pressure concentration is-0.07 Pa (one atmosphere is 0, and the pressure during reduced pressure concentration is controlled to be-0.07 MPa relative to one atmosphere), and concentrating the mixed extractive solution to obtain mixed concentrated solution with relative density of 1.1; the concentration temperature was 100 ℃.
6) Micronizing sanguis Draxonis with micronizer to obtain sanguis Draxonis superfine powder with particle diameter less than 15 μm (usually 10-15 μm);
7) adding the dragon's blood ultramicro powder into the mixed concentrated solution, stirring, uniformly mixing, and subpackaging in plastic composite film packages to prepare the traditional Chinese medicine Qi Longxuemaojian oral liquid (Qi Longxuemajian decoction) for treating dyslipidemia.
Test example 1
1. Material
1.1 Experimental animals and raising
Selecting 40 APOE-/-male mice with the age of 8 weeks, wherein the body mass (20 +/-2) g; 8C 57BL/6J wild-type male mice, body mass (20. + -. 2) g; purchased from Beijing Wintolite laboratory animal technology, Inc., license number of laboratory units: SYXK (jing) 2014-: SCXK (Kyoto) 2016-. The experiment was started after 1 week of adaptive feeding (SPF scale). Feeding in II-level animal rooms of Guangan Hospital, separating male and female animals into cages, providing regular illumination (12 hours each day and night) for 5 animals per cage, drinking sterile water, keeping the ambient temperature at 20 +/-2 ℃, keeping the relative humidity at 45% -50%, and ventilating under good conditions.
APOE-/-mice were fed high fat chow for 14 weeks; c57BL/6J wild type mice were fed with maintenance feed for 14 weeks; high-fat feed was purchased from Beijing Huafukang Biotech, Inc., and maintenance feed was provided by Sibefu (Beijing) Biotechnology, Inc.
Formula of high fat feed (also called western diet): casein, methionine, corn starch, maltodextrin, sucrose, cellulose, corn oil, anhydrous butter, mineral mixture, calcium carbonate, vitamin mixture, choline bitartrate, cholesterol, antioxidant, etc.
Maintaining the raw material composition of the feed (i.e. standard feed): corn, bean pulp, fish meal, flour, bran, salt, ammonium calcium phosphate, stone powder, various vitamins, various trace elements, amino acid and the like.
Composition table of mouse standard feed and high-fat feed
1.2 major drugs and reagents
(1) Qi longxue Mai Jian Fang: wherein, the active composition formula granules are prepared from coptis chinensis 6g (finished product batch number: 17020003), frankincense 12g (finished product batch number: 17010011), myrrh 12g (finished product batch number: 17080101), pinellia ternate 9g (finished product batch number: 17110160), trichosanthes kirilowii 15g (finished product batch number: 17050141), yam rhizome 15g (finished product batch number: 17090117), gynostemma pentaphylla 30g (finished product batch number: 17100026), poria cocos 30g (finished product batch number: 17100101) and dragon's blood 6g (finished product batch number: 1701006) according to the prescription provided by Guangan hospital pharmacy department of the academy of traditional Chinese medicine.
(2) Atorvastatin calcium tablet (lipitor): specification 20 mg/tablet × 7 tablets/box, pfeiy pharmaceutical limited, approved literature: the national drug standard J20120049;
1.3 Main instruments
BCD-258WDPM 4 ℃/-20 ℃ refrigerator (Haier, China); DW-89L388J-80 ℃ refrigerator (Haier, China); AU5822 full-automatic biochemical analyzer (Beckman, USA); Milli-Q ultrapure water purification apparatus (Merck Millipore, USA); SIM-F140AY65 automatic ice maker (Sanyo, Japan); 3-18K high speed refrigerated centrifuge (Sigma, Germany).
2. Method of producing a composite material
2.1 Experimental animal grouping and administration method
2.1.1 groups of Experimental animals
40 APOE-/-male mice with 8 weeks are randomly divided into 5 groups of model group, atorvastatin calcium group, traditional Chinese medicine Qi Longxue Jian prescription large dose group, middle dose group and small dose group, and each group comprises 8 mice; 8C 57BL/6J wild type male mice were used as a normal group.
2.1.2 drug formulation
(1) Qi longxue Mai Jianfang (granule), ground, prepared into suspension with physiological saline for clinical use, and stored in a refrigerator at 4 ℃.
(2) Atorvastatin calcium tablets are ground into powder, prepared into suspension with physiological saline for use in clinic, and stored in a refrigerator at 4 ℃.
2.1.3 methods of administration and dosages
Normal group and model group are irrigated with normal saline, atorvastatin calcium group is irrigated with atorvastatin calcium solution, and the traditional Chinese medicine Qi LONG XUE MAI JIAN formula is irrigated with suspension prepared from traditional Chinese medicine granules with corresponding dosage. The gavage time was 14 weeks. The gavage dose was 0.1ml/10g/d and was adjusted during the experiment according to the weekly body weight measurements.
(3) Normal group: the mice are subjected to intragastric administration by using normal saline, and the dosage is 0.1ml/10g/d each time and once a day;
(4) model group: the mice are subjected to intragastric administration by using normal saline, and the dosage is 0.1ml/10g/d each time and once a day;
(5) atorvastatin calcium group: the mice are given atorvastatin calcium solution (10mg/kg/d, prepared by normal saline according to the dosage of the American FDA pharmacological test), and the administration is carried out by intragastric administration, wherein the concentration is 0.1ml/10g/d every time and once a day;
(6) the qi longxue Mai Jian Fang large dose group: administering a suspension prepared from QILONGMAIJIANFANG granule for intragastric administration at a dosage of 20 times of clinical dosage of 150g decoction pieces/person/day (60 kg for example), 0.1ml/10g/d each time, once a day;
(7) the dosage group in the formula of qi longxue Mai jian is as follows: administering a suspension prepared from QILONGMAIJIANFANG granule for intragastric administration, with a dosage of 0.1ml/10g/d per time and once a day being 10 times of that of clinical dosage of 75g decoction pieces/person/day (60 kg for example);
(8) the qi longxue mai Jian Fang small dose group: the suspension prepared from the traditional Chinese medicine QILONGMAIJIANFANG granule is applied to the stomach, and the clinical dosage is 5 times of that of 37.5g decoction pieces/person/day (60 kg for example), and each time is 0.1ml/10g/d, and the administration is once a day.
2.2 anesthetizing mice
After 14 weeks, mice were fasted for 12h without water deprivation and anesthetized with isoflurane gas.
2.3 serum isolation
After anaesthetizing, the mice were bled from the orbit and placed in a biochemical tube containing the separation gel. After standing at room temperature for 2h, 3500r/min was centrifuged for 15min, and the upper serum was separated.
2.4 four measurements of blood lipid
The content of four blood lipids of each group of mice is detected by adopting a full-automatic biochemical analyzer: including total Triglycerides (TG), Total Cholesterol (TC), high density lipoprotein (HDL-C), and low density lipoprotein (LDL-C).
2.5 data analysis
The experimental data are statistically analyzed by adopting SPSS24.0 software package, and the average value plus or minus standard deviation is used for measuring the data The results are shown in Table 1.
Table 1 compositions of the invention versus ApoE-/-Effect of blood fat in mice
Note: model group VS blank, #: p < 0.01; experimental group VS model group,.: p <0.01
From the measurement results, it was found that: comparing the groups, and analyzing by using single-factor variance when the group accords with normal distribution, wherein the difference is that p is less than 0.05, and the difference has statistical significance; when the distribution is abnormal, a nonparametric test is adopted, and the difference that p is less than 0.05 has statistical significance.
The results show that at the end of 14 weeks, the model group had significantly increased levels of TC, TG and LDL-C (P <0.01) and insignificant decreases in HDL-C, compared to the blank normal group;
compared with a model group, TC, TG and LDL-C of the atorvastatin group are obviously reduced (P is less than 0.01), and the statistical difference is obvious; HDL-C was elevated, but the differences were not statistically significant (P > 0.05); TC, TG and LDL-C in a large-dose group of the traditional Chinese medicine composition are all obviously reduced (P is less than 0.01), and the statistical difference is obvious; HDL-C is elevated, but the differences are meaningless (P > 0.05); compared with the model group, the TC of the medium and small dose groups is obviously reduced (P is less than 0.01), and the statistical difference is obvious; TG and HDL-C, LDL-C were statistically insignificant compared to the model group (P > 0.05).
According to the experimental result, the traditional Chinese medicine composition for treating dyslipidemia can obviously reduce the levels of total cholesterol, triglyceride and low-density lipoprotein of mice (p is less than 0.01). It is indicated that qi longxue Mai Jian Fang has the function of reducing total cholesterol, triglyceride and low density lipoprotein in regulating dyslipidemia.
Test example 2 Observation of clinical efficacy for treating blood lipid abnormality due to accumulation of phlegm and blood stasis
Wangzhi, male, 64 years old, retired teacher, mainly because "find total cholesterol rise 5 days", come to diagnose in 2013 in 11, 19 months.
The current medical history: the patient 5 days ago involved in the unit physical examination (designated physical examination organization), and the serum biochemical examination found that the total Cholesterol (CHO) was 6.14. mu. mol/L, the low-density lipoprotein cholesterol (LDL-C) was 3.85. mu. mol/L, and no obvious abnormality was seen in triglyceride and high-density lipoprotein. The diagnosis is made for the treatment of TCM.
The following symptoms are marked: occasionally, dizziness, abdominal distension, dry and bitter mouth, no chest distress, chest pain, no expectoration, no tinnitus, no dreaminess, dry stool, 2 days 1 line, frequent urination.
History of the past: the health condition of Pinsu is general, the history of hypertension is more than 10 years, the blood pressure can reach 160/110mg, 2.5mg po qd of levoamlodipine maleate and 1.25mg po qd of Erythrophan are taken at present, and the dosage is controlled to be about 130/90 mg. The mild fatty liver was found by physical examination and was not treated. Deny the history of infectious diseases such as hepatitis, tuberculosis, deny the history of surgery and trauma, deny the history of no allergy to drugs, food and other contact.
Four diagnostic methods of traditional Chinese medicine: clear mind, free expression, normal body, correct answer, clear voice, steady smell, reddish and reddish face, purple and dark lips and tongue, yellow and greasy coating, and wiry and smooth pulse.
And (3) Western diagnosis: 1. hyperlipidemia; 2. hypertension 1 grade (middle-risk)
Traditional Chinese medicine diagnosis: blood turbidity (syndrome of intermingled phlegm and blood stasis)
Therapeutic principle: resolving phlegm, promoting blood circulation, descending turbid and dredging collaterals
Prescription: qi longxue Mai Jian Fang
The composition and decoction method of the medicine are as follows:
6g of coptis chinensis, 12g of frankincense, 12g of myrrh, 3g of dragon's blood, 9g of rhizoma pinellinae praeparata, 15g of fructus trichosanthis, 30g of gynostemma pentaphylla, 15g of poria cocos, 30g of dioscorea nipponica and seven doses, wherein one dose of the granules is taken with water every day, and the granules are taken 1 time each half an hour after breakfast and supper. The patient is advised to continue taking the antihypertensive drug, avoid drinking wine, keep the mood steady and light diet.
Second diagnosis (11 months and 26 days in 2013): the attack frequency and degree of dizziness and abdominal distension are reduced, the mouth is dry and bitter, the color of the tongue is slightly ruddy than before, the coating is thin yellow and slightly greasy, and the pulse is wiry and smooth. Blood pressure 134/88 mmHg. The powder is taken with granule in half an hour each in the morning and evening, and seven doses are added to the powder, one dose is taken every day, and 1 time is taken every half an hour after breakfast and supper.
Three diagnoses (12 months and 3 days in 2013): basically has no uncomfortable symptoms, dark red tongue, thin and yellow coating and wiry pulse. Blood pressure 128/84 mmHg. The above is slightly added or subtracted, and after the administration is finished, the biochemical items are examined, with the result of the re-diagnosis.
Four diagnostic methods (12 months and 10 days in 2013): basically has no uncomfortable symptoms, biochemical terms (2013-12-09): total Cholesterol (CHO) 5.37. mu. mol/L, low density lipoprotein cholesterol (LDL-C) 3.13. mu. mol/L. Blood pressure 128/84 mmHg. The treatment is performed for 4 weeks by adding or subtracting the above herbs without further investigation.
In the case of the treatment of dyslipidemia, shown in test example 2, the traditional Chinese medicine syndrome differentiation conforms to the syndrome of phlegm-blood stasis, and after the formula Qi Longxue pulse strengthening is taken, the total cholesterol and low-density lipoprotein are remarkably reduced, and the abnormal increase is reduced to the normal range. The clinical symptoms and signs also improve correspondingly. It is indicated that qi long blood vessel healthy formula can effectively reduce serum total cholesterol and low density lipoprotein, especially for the syndrome of intermingled phlegm and blood stasis.
The above-described embodiments of the present invention are merely exemplary and do not limit the scope of the present invention in any way. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention, and that such changes and modifications may be made without departing from the spirit and scope of the invention.
Claims (8)
1. A traditional Chinese medicine composition for preventing or treating dyslipidemia is characterized by being prepared from the following raw materials in parts by weight: 3-12 parts of coptis chinensis, 6-15 parts of frankincense, 6-15 parts of myrrh, 3-12 parts of dragon's blood, 3-9 parts of pinellia ternate, 6-15 parts of snakegourd fruit, 10-30 parts of gynostemma pentaphylla, 10-30 parts of poria cocos and 10-30 parts of dioscorea nipponica.
2. The composition as claimed in claim 1, wherein the raw materials comprise, by weight: 3-9 parts of coptis chinensis, 6-9 parts of frankincense, 6-9 parts of myrrh, 3-9 parts of dragon's blood, 6-9 parts of pinellia ternate, 9-15 parts of snakegourd fruit, 15-30 parts of gynostemma pentaphylla, 15-30 parts of poria cocos and 10-30 parts of dioscorea nipponica.
3. The composition as claimed in claim 1, wherein the raw materials comprise, by weight: coptis root 6, frankincense 9, myrrh 9, dragon's blood 6, pinellia tuber 9, snakegourd fruit 15, gynostemma pentaphylla 15, poria cocos wolf 30 and dioscorea nipponica 15.
4. The composition according to any one of claims 1 to 3, wherein the dyslipidemia is fasting TC, TG, LDL-C, HDL-C, wherein TC is 5.18mmol/L or more; TG is more than or equal to 1.70 mmol/L; LDL-C is more than or equal to 3.37 mmol/L; HDL-C is less than 1.04 mmol/L.
5. The composition according to any one of claims 1 to 3, wherein the olibanum is selected from the group consisting of stir-fried olibanum; selecting parched Myrrha as Myrrha; the rhizoma Pinelliae is rhizoma Pinelliae Preparata; the fructus trichosanthis is selected from whole fructus trichosanthis.
6. Use of a Chinese medicinal composition according to any one of claims 1 to 5 in the preparation of a medicament for the treatment or prevention of dyslipidemia.
7. The use of claim 6, wherein the dyslipidemia is phlegm-blood stasis type dyslipidemia.
8. The use according to claim 6 or 7, wherein the dyslipidemia is fasting TC, TG, LDL-C, HDL-C meeting any one of the conditions, wherein TC is greater than or equal to 5.18 mmol/L; TG is more than or equal to 1.70 mmol/L; LDL-C is more than or equal to 3.37 mmol/L; HDL-C is less than 1.04 mmol/L.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010854245.6A CN112057536B (en) | 2020-08-24 | 2020-08-24 | Traditional Chinese medicine composition for preventing or/and treating dyslipidemia and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010854245.6A CN112057536B (en) | 2020-08-24 | 2020-08-24 | Traditional Chinese medicine composition for preventing or/and treating dyslipidemia and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112057536A CN112057536A (en) | 2020-12-11 |
CN112057536B true CN112057536B (en) | 2021-12-31 |
Family
ID=73659199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010854245.6A Active CN112057536B (en) | 2020-08-24 | 2020-08-24 | Traditional Chinese medicine composition for preventing or/and treating dyslipidemia and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112057536B (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101396516A (en) * | 2007-09-29 | 2009-04-01 | 刘若宽 | Medicine for treating hypertension |
CN102423382A (en) * | 2011-11-21 | 2012-04-25 | 何庆勇 | Chinese medicine composition for treating dyslipidemia and application thereof |
CN105770745A (en) * | 2016-04-13 | 2016-07-20 | 河南省傅潭酒业有限公司 | Traditional Chinese medicine liquor for treating dyslipidemia and preparation method thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8647685B1 (en) * | 2012-08-03 | 2014-02-11 | Timing Pharmaceutical Co., Ltd. | Composite of herbal extracts for lowering blood lipid and medication comprising the said composite |
-
2020
- 2020-08-24 CN CN202010854245.6A patent/CN112057536B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101396516A (en) * | 2007-09-29 | 2009-04-01 | 刘若宽 | Medicine for treating hypertension |
CN102423382A (en) * | 2011-11-21 | 2012-04-25 | 何庆勇 | Chinese medicine composition for treating dyslipidemia and application thereof |
CN105770745A (en) * | 2016-04-13 | 2016-07-20 | 河南省傅潭酒业有限公司 | Traditional Chinese medicine liquor for treating dyslipidemia and preparation method thereof |
Non-Patent Citations (1)
Title |
---|
化痰活血方对高脂血症大鼠血液流变学的影响;叶勇;梅国强;刘松林;雍雪莲;张茂林;梅杰;《湖北中医学院学报》;20050920;第7卷(第03期);11-13 * |
Also Published As
Publication number | Publication date |
---|---|
CN112057536A (en) | 2020-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111407877A (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia, preparation method, detection method and application thereof | |
EP1732578A1 (en) | Plant-based medicament for the treatment of hepatitis c | |
WO2014094632A1 (en) | Pharmaceutical composition for treating headache, and preparation method thereof | |
CN111012876A (en) | Product for improving sleep and preparation method and application thereof | |
CN103386022A (en) | Chinese medicine composition for treating tuberculous pleurisy | |
CN110882309A (en) | Traditional Chinese medicine composition for treating chicken synovial capsule mycoplasma disease and preparation method thereof | |
Li | Chinese herbal medicine | |
CN103961614B (en) | Chinese medicine composition for treating respiratory disease and its production and use | |
CN101537160B (en) | Health product for toxicant elimination and beauty maintenance | |
CN103690582B (en) | A kind of compositions and application thereof containing dendrobium polysaccharide and atractylis concrete | |
CN103142916B (en) | Medicament for preventing and treating senile dementia and preparation method thereof | |
CN111110735A (en) | Lipid-lowering pharmaceutical composition, preparation method and application | |
CN110652552A (en) | Wound healing formula and preparation method | |
JP2006514041A (en) | Composition for suppressing obesity using mixed herbal materials | |
CN112057536B (en) | Traditional Chinese medicine composition for preventing or/and treating dyslipidemia and application thereof | |
CN102526639B (en) | Chinese medicinal composition for treating hyperlipidemia and preparation method thereof | |
CN112057535B (en) | Preparation method of traditional Chinese medicine composition for preventing or/and treating dyslipidemia | |
CN112089784A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diseases caused by atherosclerosis | |
CN112089783B (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity | |
CN107997170B (en) | Composition with blood fat reducing function and preparation method thereof | |
CN105267711A (en) | Pharmaceutical preparation for treating vertigo | |
CN111084878A (en) | Biological medicine and medical total nutrient food for lung and respiratory system diseases and preparation method thereof | |
CN114533835B (en) | A Chinese medicinal composition with effects of removing pathogenic wind and dampness, and its preparation method | |
CN103623109A (en) | Traditional Chinese medicine composition for treating ischemic cerebrovascular disease and preparation method thereof | |
CN114712466B (en) | Medicine with weight-reducing and beautifying effects and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |